Solid Tumor Oncology
Includes Bone and Connective Tissue Program, Breast Cancer Program, Colorectal Cancer Program, Endocrine Cancer Program, Eye/Orbital Cancer Program, Geriatric Oncology Program, Head & Neck Cancer Program, Liver, Pancreas and Bile Duct Cancer Programs, Prostate and Urologic Cancer Programs, Skin Cancer Program, Thoracic Cancer Program (Lung and Esophageal Cancers)
Dr. Alqwasmi's research interests include breast cancer.
Dr. Bylow's research interest is in the treatment of genitourinary malignancies. She has a long-standing research interest in geriatric oncology and the long-term effects of cancer therapies. She is currently studying nutritional methods to forestall the loss of muscle mass seen in men treated with anti-androgen therapy in prostate cancer.
Dr. Chakrabarti is a gastrointestinal (GI) oncologist with a primary interest in colorectal cancer, gastroesophageal cancer, and biliary tract cancer, with a particular emphasis on translational and clinical research. His principal area of research includes the utilization of circulating tumor DNA (ctDNA) in assessing treatment response and the presence of minimal residual disease after surgery, immunotherapy in GI cancers, the study of prognostic/predictive biomarkers in colorectal and gastroesophageal cancer, and evaluating novel therapies in advanced GI cancers. He leads several trials as the principal investigator and collaborates with investigators in other institutions, including Mayo Clinic (Rochester, MN). He has published extensively in the field of GI cancers.
Dr. Charlson's research interests are focused on the care of patients with sarcoma and young adult cancer patients. Current efforts include chemotherapy clinical trials, evaluation of several potential biomarkers of treatment response, and cancer care process improvement.
Dr. Chaudhary's primary research interest is to better understand the biology of breast cancer tumors, as well as different hormone receptors and how they impact patient outcomes. She is working to identify new drug therapies to overcome cancer cell growth. Her investigator initiated clinical trial assessing neoadjuvant endocrine therapy and tumor molecular changes in patients with breast cancer was the recipient of funding from the Rock River Foundation and the MCW Cancer Center in 2017. Another investigator initiated clinical trial assessing the role of PD-1 inhibition in breast cancer patients undergoing neoadjuvant chemotherapy was recently funded by a CTSI KL-2 grant funded by Advancing a Healthier Wisconsin Research and Education Program (AHW REP).
Dr. Chen is a physician scientist and thoracic medical oncologist whose research mission is to enable discovery of new therapeutic vulnerabilities in advanced solid cancers by leveraging her expertise in translational genomics and rapid research autopsy. She was a recipient of the ASCO Conquer Cancer Foundation Young Investigator Award (2018-2019). Her research is currently supported by an NCI K08 Mentored Clinical Scientist Research Career Development Award (2019-2024) and focuses on elucidating mechanisms of therapeutic resistance in relapsed small cell lung cancer through multi-omics characterization of metastatic tumor tissues and pre-clinical validation studies. Dr. Chen was formerly a faculty member at The Ohio State University College of Medicine and Comprehensive Cancer Center in Columbus, Ohio (2019-2021). She is new to MCW and looks forward to forming new research and clinical collaborations to improve the care of lung cancer patients in Wisconsin.
Dr. Cheng's research interest is in the development of clinical trials focusing on the investigative use of chemotherapy and/or novel therapy in high risk breast cancer cases such as triple negative breast cancer or inflammatory breast cancer particularly in the pre-operative setting.
Dr. George's research focus is on pancreatic and gastro-esophageal cancers. He is interested in experimental therapeutics, specifically, clinical trials targeting putative molecular mechanisms involved in the development and progression of gastrointestinal malignancies. He chairs the Molecular Tumor Board - a monthly meeting that analyzes genomic alterations in tumors to identify appropriate targeted treatment options. Further, he represents Froedtert and the Medical College of Wisconsin at the Precision Medicine Exchange Consortium, of which MCW is a founding member. The goal of the consortium is to pool clinically annotated molecular data among member institutions and use that information to develop clinical trials aimed at actionable genomic alterations. He is the institutional Principal Investigator on several clinical trials in both Pancreatic and Gastro-esophageal Cancers.
Dr. Giever's main research interest is to enroll patients on genitourinary clinical trials. Additionally, he would like to build a robust general oncology clinical trial portfolio at the Drexel Town Square Health Center Cancer Center within the Froedtert Community Cancer Network and Division of Hematology and Oncology.
Dr. Kamaraju has research interest in breast cancer and more specifically, how breast cancer mortality rates can be reduced in vulnerable, and underserved populations through community-based initiatives, for which she has received several Susan G. Komen grants. She works with Patient Centered Outcomes Research (PCOR) evaluating cancer treatment related toxicities and cancer survivorship disparities.
Dr. Kilari's research focuses on genitourinary cancers, including early phase and translational trials. Dr. Kilari and his collaborators are also studying how copper transport proteins play an important role in the sensitivity of cancer cells to platinum-based chemotherapy, as well as the role of exosomes micro RNAs in predicting treatment responses in men with prostate cancer. He is also the Principal investigator of a phase 2 study looking at the role of upfront enzalutamide and dutasteride for elderly men with systemic prostate cancer. He is actively involved in outcomes research at the Clement J Zablocki VA Medical Center.
Dr. Mittal's research interests are in cooperative group clinical trials and drug development.
Dr. Taylor's research interest is in head and neck cancers and malignant hematology.
Dr. Thompson has interest in clinical and translational research related to thoracic malignancies, particularly regarding the use of immunotherapy and novel agents for the treatment of lung cancer. He is also interested in immunotherapy-related side effects and participates in translational and clinical research in this field.
Dr. Wiger's research interests are in maintaining resiliency among practitioners as well as exploring quality improvement opportunities and hospital readmissions issues specific to inpatient oncology.
Dr. Wong conducts clinical research evaluating novel therapies for head and neck cancer, and in particular, agents that are used concurrently with radiation therapy. His research efforts include NCI funded clinical trials. His research also focuses on national patterns of care for head and neck cancer treatment, and mitigation of toxicity from head and neck cancer treatment, and cancer prevention. Dr. Wong is the lead investigator for the Lead Academic Participating Site (LAPS) of the NCI’s National Clinical Trial Network at MCW. MCW is one of the top 32 institutions in the country to receive a LAPS award. He also received an RO1 NIH grant with Ming You, MD. PhD, to study a new agent in patients with oral cancer.